Tyche Wealth Partners LLC Takes $63,000 Position in SeaStar Medical Holding Corporation (NASDAQ:ICU)

Tyche Wealth Partners LLC bought a new position in SeaStar Medical Holding Corporation (NASDAQ:ICU) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 37,700 shares of the company’s stock, valued at approximately $63,000. Tyche Wealth Partners LLC owned about 0.43% of SeaStar Medical as of its most recent SEC filing.

Separately, Geode Capital Management LLC raised its position in shares of SeaStar Medical by 14.1% in the fourth quarter. Geode Capital Management LLC now owns 45,430 shares of the company’s stock worth $88,000 after acquiring an additional 5,618 shares during the period. Institutional investors and hedge funds own 1.69% of the company’s stock.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded SeaStar Medical from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd.

SeaStar Medical Trading Up 17.6%

Shares of ICU stock opened at $0.42 on Thursday. SeaStar Medical Holding Corporation has a 12-month low of $0.31 and a 12-month high of $13.85. The business’s 50 day moving average is $1.16 and its two-hundred day moving average is $1.59. The company has a market capitalization of $4.74 million, a P/E ratio of -0.12 and a beta of -0.89.

SeaStar Medical (NASDAQ:ICU) last announced its earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.08. The business had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.15 million.

SeaStar Medical Company Profile

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.